Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock By Investing.com
Cantor Fitzgerald has reiterated an Overweight rating on Summit Therapeutics (NASDAQ:SMMT) despite concerns regarding the HARMONi-3 trial results for its ivonescimab drug. Medical experts are reportedly less discouraged by the interim progression-free survival miss, anticipating strong overall survival data from a related China-only trial. The firm suggests that skepticism surrounding HARMONi-3 may be overstated, while other analysts have presented mixed views on the company's prospects.
Bernstein Initiates Summit Therapeutics at Underperform
Bernstein has initiated coverage on Summit Therapeutics with an "Underperform" rating. This follows a recent downgrade from HC Wainwright, which moved Summit Therapeutics from "Buy" to "Neutral." The company's lead candidate, ivonescimab, is a bispecific antibody in multiple Phase III clinical trials for non-small cell lung cancer and other solid tumors.
Is Summit’s Ivonescimab Oncology Bet Reshaping The Investment Case For Summit Therapeutics (SMMT)?
Summit Therapeutics is gaining attention for its late-stage bispecific antibody, ivonescimab, for non-small cell lung cancer and colorectal cancer, despite current unprofitability and negative earnings. The company's significant R&D investment is seen as a key factor in reshaping its long-term role in oncology, with investors closely watching the U.S. regulatory progress for ivonescimab. Analyst forecasts for Summit Therapeutics project substantial revenue and earnings growth by 2029, suggesting a significant upside to its current stock price, though funding risks remain.
Is Summit’s Ivonescimab Oncology Bet Reshaping The Investment Case For Summit Therapeutics (SMMT)?
Summit Therapeutics is gaining attention for its late-stage ivonescimab, a bispecific antibody for non-small cell lung cancer and colorectal cancer, despite current unprofitability. The company's significant R&D investment and focus on this therapy are influencing its long-term investment outlook, with a key near-term catalyst being the U.S. regulatory progress on the HARMONi BLA for ivonescimab, despite ongoing financial risks. Forecasts suggest substantial revenue and earnings growth by 2029, implying a significant increase in its fair value.
Summit Therapeutics (NasdaqGM:SMMT) Stock Forecast & Analyst Predictions
Summit Therapeutics is facing financial pressure and has highlighted a significant going concern risk due to insufficient cash, despite its lead drug candidate, ivonescimab, progressing through late-stage clinical trials for various cancers. Analysts forecast significant earnings and revenue growth, though the company is expected to remain unprofitable for the next three years. Key areas to watch include financing developments and upcoming clinical trial readouts for ivonescimab, which has shown promise in improving progression-free survival in NSCLC trials but also faces uncertainties regarding overall survival benefits and global approval.
A Look At Summit Therapeutics (SMMT) Valuation After HARMONi-3 Downgrade And Wider Quarterly Loss
Summit Therapeutics (SMMT) has received a downgrade from H.C. Wainwright due to weaker interim HARMONi-3 trial signals and reported a wider first-quarter net loss of US$189.42 million. Despite these setbacks and a 6.19% stock dip over the past month, the share price remains up 28.43% over 90 days. A prevalent narrative suggests SMMT is 35.6% undervalued with a fair value of $29.18, banking on future revenue growth from its ivonescimab clinical activity, though this hinges on the success of its single lead asset.
H.C. Wainwright Reduced its Price Goal on Summit Therapeutics Inc. (SMMT)
H.C. Wainwright has lowered its price target for Summit Therapeutics Inc. (SMMT) from $30 to $23, citing a weaker interim signal from HARMONi-3 and increased risk for the upcoming squamous readout. This adjustment follows Summit Therapeutics' first-quarter 2026 results, which included nearly $600 million in cash and growing GAAP operating costs. Despite acknowledging potential risks, H.C. Wainwright suggests that certain AI stocks may offer higher and quicker returns than SMMT.
8 Most Promising Biotech Stocks to Buy Now
This article highlights Summit Therapeutics Inc. (NASDAQ:SMMT) as one of the promising biotech stocks. It discusses recent financial results, including a reduction in its price target by H.C. Wainwright, and mentions the progress of its main product, Ridinilazole, in Phase III clinical research. The article also touches upon the independent monitoring committee's recommendation to continue the HARMONi-3 squamous cohort.
Summit Therapeutics (SMMT) Is Down 20.1% After Q1 2026 Net Loss Widens Sharply
Summit Therapeutics (SMMT) experienced a sharp 20.1% drop in stock value after reporting a significant widening of its Q1 2026 net loss to US$189.42 million from US$62.91 million a year earlier, prompting concerns about its cash use and funding needs. This increased loss raises questions about the company's ability to fund its extensive late-stage oncology program for ivonescimab, despite the FDA's acceptance of its BLA with a target action date of November 14, 2026. The financial results highlight the tension between rising losses and the company's reliance on ivonescimab for future growth, leading analysts to potentially revise their optimistic forecasts.
A Look At Summit Therapeutics (SMMT) Valuation After Trial Update And Going Concern Warning
Summit Therapeutics (SMMT) experienced a sharp stock drop after its Phase III ivonescimab trial showed no early efficacy signal, coupled with wider first-quarter losses and a going concern warning. Despite significant long-term shareholder returns, the market reacted negatively, contrasting with analyst targets suggesting a substantial undervaluation based on future earnings potential from its broad clinical pipeline. However, concerns remain regarding high R&D spending and a high price-to-book ratio compared to industry peers.
Summit Therapeutics Inc. Shareholders Are Encouraged to
Johnson Fistel, PLLP is investigating potential claims on behalf of investors in Summit Therapeutics Inc. (NASDAQ: SMMT) following a sharp decline in stock price. This decline occurred after the company's disclosure regarding its HARMONi-3 Phase III clinical trial and the Independent Data Monitoring Committee's recommendation to continue the study despite an early interim progression-free survival analysis. The law firm is examining whether Summit complied with federal securities laws and encourages affected shareholders to join their investigation.
Summit Therapeutics Stock Plunges As Selling Pressure Intensifies
Summit Therapeutics Inc. (SMMT) stock plunged by 24.51% due to negative sentiment surrounding its latest clinical trial developments. Analysts highlight the company's negative profitability and lack of revenue growth, despite a liquid balance sheet. Technically, SMMT is in a short-term downtrend, making it a high-risk, pre-commercial biotech stock.
Summit Therapeutics (SMMT) Is Down 27.0% After HARMONi-6 OS Plenary, BLA Progress And Wider Losses - Has The Bull Case Changed?
Summit Therapeutics reported widening net losses for Q1 2026 and a 27% stock drop, amidst significant clinical and regulatory advancements for its lead asset, ivonescimab. The company is progressing with multiple Phase III trials and has received FDA acceptance for its Biologics License Application, with a PDUFA date set for November 14, 2026. However, rising losses and a finite cash runway pose risks, concentrating investor attention on whether ivonescimab can justify the heavy investment and secure future funding.
SMMT Plunges As Summit Therapeutics Stock Sheds Over 27%
Summit Therapeutics Inc. (SMMT) stock plunged over 27% amidst concerns about its clinical trial updates, trading down by -24.51%. The company remains a high-risk, pre-commercial biotech with deeply negative profitability, despite a strong balance sheet and solid liquidity. Analysts expect continued volatility with a bearish bias, emphasizing that traders are paying for future potential rather than current earnings.
Summit Therapeutics Shares Fall After 1Q Loss Widens
Summit Therapeutics reported a wider net loss of $29.9 million in the first quarter of 2026, or 10 cents per share, compared to a loss of $15.5 million, or 6 cents per share, in the same period last year. This increased loss led to a drop in the company's shares in premarket trading. The company also announced a new strategy for its lead antibody-drug conjugate, akesobeglimab, focusing on non-small cell lung cancer as a monotherapy.
U.S. Markets Closed Mixed Friday As Pershing Square Led, Summit Therapeutics Lagged
U.S. stock markets closed mixed on Friday, with the NASDAQ Composite Index and S&P 500 Index seeing gains, while the Dow declined. Pershing Square led the market, and Summit Therapeutics lagged behind.
Summit Therapeutics (SMMT) Shares Drop 22% After Trial Update
Summit Therapeutics (SMMT) saw its shares drop 22% after announcing that its late-stage HARMONi-3 trial for ivonescimab, a treatment for metastatic non-small cell lung cancer, would proceed as planned following an interim analysis. While the independent committee found no concerns, the market reacted negatively, potentially hoping for stronger positive signals. The company, which has strong financial stability but low profitability, awaits final trial results in H2 2026.
Summit Therapeutics price target lowered to $16 from $17 at Piper Sandler
Piper Sandler has reduced its price target for Summit Therapeutics (SMMT) to $16 from $17, maintaining a Neutral rating. This adjustment follows Summit's Q1 earnings report, which included an interim PFS analysis that recommended the continuation of the study. Investors are reportedly concerned about the replicability of strong effect sizes seen in other studies, despite minimal interim alpha.
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial
Summit Therapeutics' stock declined following an update on its Phase 3 clinical trial for acera targeting non-small cell lung cancer, partnered with Akeso. The update indicated a slower-than-expected patient enrollment rate due to increased screening failures. This delay impacts the previous timeline for trial completion and potential market entry.
Summit Therapeutics Stock Dips After Q1 Financial Report
Summit Therapeutics (NASDAQ: SMMT) shares significantly declined after its first-quarter financial report, despite a better-than-expected Non-GAAP EPS loss. The dip is attributed to increased spending, widening losses, and a lack of immediate clinical catalysts, with non-GAAP net loss nearly tripling and operating expenses more than doubling year-over-year. Cash and short-term investments also decreased due to accelerated cash usage.
Goldman Sachs Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $41
Goldman Sachs has reaffirmed its Buy rating for Summit Therapeutics (SMMT.US) and maintained its target price at $41. This indicates continued confidence from the investment bank in the company's prospects.
Summit Therapeutics stock falls after Q1 update (SMMT:NASDAQ)
Summit Therapeutics (SMMT) saw a significant stock drop of approximately 22% following an announcement that a late-stage trial for its lead drug, ivonescimab, developed with Akeso (AKESF), will proceed as planned after an interim analysis. The clinical trial, focusing on lung cancer, did not yield any immediate positive news, causing the market reaction.
Merck's Biggest Looming Rival In Cancer Just Took A Gut Punch
Summit Therapeutics' stock plummeted after an interim analysis showed its experimental lung cancer treatment, ivonescimab plus chemotherapy, did not meet expectations. This treatment was seen as a potential competitor to Merck's Keytruda. Despite the setback, Summit Therapeutics plans to continue testing the treatment until a final analysis in the second quarter.
Summit Therapeutics PLC $SMMT Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA reduced its stake in Summit Therapeutics PLC by 13.7% in Q4, selling 220,388 shares. Despite this, other institutional investors like Vanguard Group Inc. increased their holdings, and 4.61% of the stock is currently owned by institutional investors. Summit Therapeutics missed its quarterly EPS estimates and holds a "Moderate Buy" consensus rating from analysts with an average target price of $31.00.
Summit Therapeutics Inc. 1Q 2026: Revenue ($189.52M), EPS ($0.24) — 10-Q Summary
Summit Therapeutics Inc. reported its first-quarter 2026 results, showing a wider comprehensive loss of ($189.42M) due to increased R&D and G&A spending as the company expanded its global Phase III clinical programs. Key highlights include the FDA's acceptance of a BLA for ivonescimab with a PDUFA date of November 14, 2026, and consistent efficacy data across diverse populations for its HARMONi trial. The company continues to advance its pipeline and collaborations while scaling operations.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Summit Therapeutics announced its financial results and operational progress for the first quarter ended March 31, 2026, highlighting significant advancements in the clinical development of ivonescimab (SMT112) for non-small cell lung cancer (NSCLC) and other solid tumors. The company reported a GAAP net loss of $189.4 million and detailed the progress of multiple Phase III trials, including the upcoming presentation of HARMONi-6 overall survival data at ASCO 2026 and anticipated data readouts for other HARMONi studies in 2026 and 2027. Summit also noted continued expansion of its clinical collaborations and a strong cash position of $598.7 million.
Summit Therapeutics (NASDAQ: SMMT) posts larger Q1 loss amid cash burn and trials
Summit Therapeutics (NASDAQ: SMMT) reported a significantly larger net loss of $189.4 million in Q1 2026, compared to $62.9 million in the prior year, primarily due to increased research and development expenses for its lead cancer drug ivonescimab and higher stock-based compensation. The company's cash and short-term investments of $598.7 million as of March 31, 2026, are deemed insufficient to fund operations for at least one year, raising substantial doubt about its ability to continue as a going concern. The FDA has accepted the Biologics License Application for ivonescimab, with a PDUFA date of November 14, 2026, but has indicated that a statistically significant overall survival benefit will be necessary for potential approval.
Clear Street Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $31
Clear Street has reiterated its Buy rating for Summit Therapeutics (SMMT.US) but has reduced its target price for the stock from $33 to $31. This adjustment reflects a continued positive outlook on the company despite a slight decrease in valuation.
Summit Therapeutics PLC (Nasdaq: SMMT) recently disclosed its financial report and business development updates for the first quarter ending March 31, 2026.
Summit Therapeutics PLC (Nasdaq: SMMT) has released its financial report and business development updates for the first quarter ending March 31, 2026. The company highlighted its ongoing advancements in core R&D, focusing on innovative therapies and milestone progress in key projects. Financially, Summit Therapeutics detailed its revenue, R&D investment, and cash flow, emphasizing prudent financial control to support long-term objectives and commercialization.
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026
Summit Therapeutics announced its financial results for the first quarter ended March 31, 2026, alongside updates on the clinical and operational progress of its investigational bispecific antibody, ivonescimab. Key highlights include upcoming overall survival data from the HARMONi-6 trial at ASCO 2026, ongoing enrollment in other Phase III studies for various cancers, and increases in GAAP and Non-GAAP operating expenses primarily due to clinical study expansion and stock-based compensation modifications. The company reported $598.7 million in cash and short-term investments and a GAAP net loss of $189.4 million for the quarter.
Summit Therapeutics (NASDAQ: SMMT) ramps ivonescimab trials, widens Q1 2026 net loss
Summit Therapeutics reported a widened GAAP net loss of $189.4 million and increased operating expenses in Q1 2026, primarily due to higher stock-based compensation and accelerated development of its cancer drug, ivonescimab. Despite the losses, the company maintains a robust cash reserve of $598.7 million and highlighted significant clinical milestones for ivonescimab, including an accepted BLA with an FDA PDUFA goal date of November 14, 2026, and upcoming ASCO Plenary Session data. The company is actively pursuing several Phase III trials and collaborations to expand ivonescimab's potential indications.
Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q1 Adjusted Loss $0.15 per Share, vs. FactSet Est of $-0.17
Summit Therapeutics Inc. (SMMT) reported an adjusted loss of $0.15 per share for the first quarter, which is better than the FactSet estimate of a $0.17 loss per share. The company's stock, SMMT, showed a 5-day change of +3.02% and a year-to-date change of +22.70% as of April 30, 2026. Summit Therapeutics is focused on developing ivonescimab, a bispecific antibody for non-small cell lung cancer treatment.
Summit Therapeutics (SMMT) Leads Healthcare Stocks with 372.66% CapEx Growth
Summit Therapeutics (SMMT) reported a significant 372.66% year-over-year capital expenditure growth to $657,000 for fiscal 2025, driven by its focus on developing ivonescimab for lung cancer. Despite this strategic investment and strong financial strength with a 9.87 current ratio, the company holds a low GF Score™ of 37/100 due to profitability challenges. Investors are advised to exercise caution, as the stock trades at a high price-to-book ratio and lacks positive earnings.
Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth (XLV:NYSEARCA)
Summit Therapeutics is leading U.S. large-cap healthcare stocks in year-over-year capital expenditure (CapEx) growth, signaling strong investment in future expansion, particularly for its lung cancer candidate. Other companies like Penumbra and United Therapeutics also show high CapEx growth, although most of these stocks currently hold "Hold" ratings, suggesting market pricing already reflects these investments. Insulet is expanding manufacturing for Omnipod growth, highlighting diverse operational drivers for CapEx increases across the sector.
Summit Therapeutics Inc. (SMMT) Stock Analysis: Exploring A 40.93% Potential Upside
Summit Therapeutics Inc. (SMMT) is a biopharmaceutical company with a potential upside of 40.93%, based on an average target price of $31.12. The company, which is developing ivonescimab for cancers like NSCLC and colorectal cancer, has a market capitalization of $17.14 billion and strong analytical support despite current financial challenges typical of a clinical-stage biotech. Its strategic focus on innovative cancer therapies and global market reach position it for significant growth if its pipeline products are successfully commercialized.
Trading Systems Reacting to (SMMT) Volatility
This article analyzes Summit Therapeutics Inc. (SMMT) stock volatility, identifying mixed sentiment and elevated downside risk across various time horizons. It presents three AI-generated institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal data for near-term, mid-term, and long-term outlooks.
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Average Rating of "Moderate Buy" from Analysts
Eighteen analysts have given Summit Therapeutics (NASDAQ:SMMT) a consensus "Moderate Buy" rating, with an average 12-month price target of $31.00. Recent analyst activity includes new "buy" ratings from Stifel and Citigroup, while HC Wainwright adjusted its target to $30.00 and Zacks upgraded the stock to "hold". Despite missing its last EPS estimate, the company's shares are trading around $22.08, with a market capitalization of $17.14 billion.
Investors Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)
Investors recently bought a significantly higher volume of call options for Summit Therapeutics (NASDAQ:SMMT), with 16,625 call options traded, a 387% increase from the typical volume. This indicates a strong bullish sentiment, despite the company's recent earnings miss and a stock price drop on high volume. Analyst ratings for SMMT are mixed, ranging from "sell" to "strong buy," with a consensus of "Moderate Buy" and an average price target of $31.00.
Summit Therapeutics (NASDAQ:SMMT) Shares Down 6.2% - Time to Sell?
Summit Therapeutics (NASDAQ:SMMT) saw its shares drop 6.2% to $24.74 on Wednesday, with trading volume significantly below average. The company missed quarterly EPS estimates, and its analyst coverage is mixed, ranging from "Strong Buy" to "Sell," with an average price target of $31.00. Despite the recent dip and missed earnings, the company's lead drug, ridinilazole, has Fast Track and QIDP designations, and institutional investors have recently increased their stakes.
Summit Therapeutics (NASDAQ:SMMT) Sees Strong Trading Volume - Here's Why
Summit Therapeutics (NASDAQ:SMMT) experienced a significant surge in trading volume, with shares up 81% from the previous session. The stock closed at $26.0280, up from $25.12, despite the company reporting a wider-than-expected quarterly loss of ($0.29) EPS. Analyst ratings are mixed, leading to a "Moderate Buy" consensus and a target price of $31.00.
Stifel reiterates Summit Therapeutics stock rating on trial data By Investing.com
Stifel has reiterated a Buy rating and a $45.00 price target for Summit Therapeutics (NASDAQ:SMMT) following the disclosure of HARMONi-6 interim Overall Survival readout data. The stock has seen a significant year-to-date increase, partly due to expectations from upcoming trial results. Other analysts like UBS and Cantor Fitzgerald also maintain Buy/Overweight ratings, while Jefferies downgraded to Hold due to perceived risks.
Summit Therapeutics has scarcity value in a crowded drug race: Analyst
This article mentions that Summit Therapeutics possesses scarcity value in the competitive drug development landscape, according to an unnamed analyst. The content provided is minimal, only stating the title and a time of publication.
Evercore Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $34
Evercore has reiterated its Buy rating for Summit Therapeutics (SMMT.US) and maintained its price target of $34. This indicates a continued positive outlook from the firm regarding the company's stock performance.
SMMT Technical Analysis | Trend, Signals & Chart Patterns | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT)
This article provides a technical analysis of SUMMIT THERAPEUTICS INC (NASDAQ:SMMT), giving it a technical rating of 8 out of 10 due to decent short and medium-term performance and positive trends. Despite the strong rating, it warns that the stock is currently overbought and extended, suggesting waiting for a consolidation before entry. The analysis details support and resistance levels, various indicator signals, and mentions several daily and weekly candlestick and chart patterns.
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement
Summit Therapeutics Inc (SMMT) saw its stock rise by 12.03% on April 16, driven by positive analyst ratings and the FDA's acceptance of its Biologics License Application (BLA) for ivonescimab. The BLA targets EGFR-mutated non-small cell lung cancer with a PDUFA date in November 2026, supported by strong Phase III HARMONi study data. Increased institutional investor holdings also contributed to the upward momentum, despite some acknowledged risks and past downgrades.
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing
This article analyzes Summit Therapeutics Inc. (SMMT) through an AI-driven quantitative research lens, focusing on its impact on rotational strategy timing. It highlights strong near and mid-term sentiment but a weak long-term outlook for SMMT, indicating elevated downside risk. The analysis provides specific institutional trading strategies, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Summit Therapeutics Stock Slumps After Partner Akeso Gets FDA Nod For Cancer Drug: Retail’s Optimistic
Summit Therapeutics' stock (SMMT) saw a significant drop following its partner Akeso's FDA approval for their cancer drug, citing a clinical hold on a pivotal study. Despite this, retail investors are showing optimism with increased stock purchases, betting on a reversal driven by the drug's potential. The stock experienced extreme volatility, with a sharp decline but eventual recovery from its lows, indicating mixed market sentiment.
SMMT News | SUMMIT THERAPEUTICS INC (NASDAQ:SMMT)
This page provides news and information for SUMMIT THERAPEUTICS INC (NASDAQ:SMMT). It includes the current stock price, after-hours trading data, and links to various security sections such as stock charts, financial analysis, and earnings reports. The page also offers "All Press Releases" for the company.
This Inhibrx Biosciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Wednesday
This article highlights four new analyst initiations on various companies. Stifel initiated coverage on Inhibrx Biosciences Inc and Summit Therapeutics Inc with Buy ratings. Needham started coverage on MapLight Therapeutics Inc with a Buy rating, while Evercore ISI Group began coverage on Elevance Health Inc with an In-Line rating.
Citigroup starts coverage of Summit Therapeutics Inc (SMMT), Apr 08 2026, Buy
Citigroup has initiated coverage of Summit Therapeutics Inc. (SMMT) with a "Buy" rating on April 8, 2026, noting the stock's "scarcity value" in a competitive drug market. While no price target was provided, this new institutional rating highlights the company's drug pipeline and competitive positioning. Meyka AI rates SMMT with a "B" grade, suggesting relative strength compared to benchmarks and sector trends.
